Research and Markets: Renal Cell Carcinoma and Multiple Myeloma: Leaders Emerge, But Plenty of Room for Numerous Competitors - ASCO Review Part I - A Summary of Highlights Presented At the ASCO 2006 Annual Meeting.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42593) has announced the addition of Financial Markets Research: ASCO ASCO American Society of Clinical Oncology ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland) ASCO Australian Standard Classification of Occupations ASCO Automatic Switch Company Review Part I - A Summary of Highlights Presented at the ASCO 2006 Annual Meeting to their offering. ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presented are comments on the most important events at the 2006 conference. Scope of this title: * Provides a summary of highlights presented at ASCO 2006 on Friday June 2, 2006 through Sunday June 4, 2006 * Drugs covered include Amgens denosumab (AMG-162), AstraZenecas Zactima (vandetanib/ZD6474), and Bristol-Myers Squibbs Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Sprycel (dasatinib) Highlights of this title: * GlaxoSmithKlines lapatinib should represent a new standard of care for patients for HER2+ metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast cancer patients that have progressed after Herceptin. Furthermore, the strength of lapatinib in a post-Herceptin setting supports the development of this drug in earlier settings. * Following dasatinibs favorable review by an FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. panel, we believe data presented at ASCO is likely to have a very positive impact on the rate of uptake of dasatinib. * Advantage in the renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. market has shifted to PFEs Sutent after data comparing BAY/ONXXs Nexavar to interferon in the front-line setting was not ready to be presented, thus opening the door for Sutent. Reasons to read this report: * Identify the most important events that occurred at ASCO 2006 * Understand the impact of key data presentations on the potential future dynamics of the oncology market The contents contained inside this report include: Summary Renal cell carcinoma and multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility : leaders emerge, but plenty of room for numerous competitors ASCO Coverage Key highlights Highlights In Renal Cell Carcinoma Focus on renal cell carcinoma continues at ASCO Sequential targeted therapy looks promising, but case against EGFR EGFR Epidermal Growth Factor Receptor (a kinase enzyme) EGFR Estimated Glomerular Filtration Rate inhibition builds Reports of "failure" are misleading, but Nexavar yet to prove survival benefit Renal cell summary: Sutent and temsirolimus step forward while Nexavar stands still Highlights In Multiple Myeloma Three agents offer significant clinical benefit Thalomid-containing regimens now have time to progression and survival benefit data Thalomid data in newly diagnosed elderly patients impressive but unlikely to have major impact on treatment Median overall survival for Revlimid in relapsed and refractory refractory Material that is not deformed or damaged by high temperatures, used to make crucibles, incinerators, insulation, and furnaces, particularly metallurgical furnaces. disease recently reached Uncertainty surrounds Revlimids efficacy in Thalomid failures With risk factors for thromboembolism thromboembolism /throm·bo·em·bo·lism/ (-em´bo-lizm) obstruction of a blood vessel with thrombotic material carried by the blood from the site of origin to plug another vessel. throm·bo·em·bo·lism n. identified, Revlimid can be used more safely Optimal treatment algorithm remains undetermined - which treatment will be used upfront? Appendix Our Healthcare Disclosure information Ask the analyst For more information visit http://www.researchandmarkets.com/reports/c42593 Source: Datamonitor |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion